ISUABXIS, a subsidiary of the ISU Group, focuses on the research and development of biopharmaceuticals as its main business. It has successfully developed and is producing and selling treatments both domestically and internationally, including Abcertin for Gaucher disease, Fabagal for Fabry disease, and Clotinab, an antibody therapy that inhibits thrombosis. In addition to the R&D, production, and sale of biopharmaceuticals, the company also imports and sells rare medicines, including treatments for urea cycle disorders and Wilson's disease.

ISU104 (an ErbB3-targeting antibody therapy) is an anticancer drug that inhibits the growth of cancer cells caused by ErbB3 protein expression. It has completed Phase 1 clinical trials in adult patients with solid tumors, as well as recurrent or metastatic head and neck cancer that has failed standard treatments, confirming its safety and efficacy. Additionally, ISU104 is being developed as an anticancer immunotherapy using CAR-NK technology. ABX2001, a novel immunotherapy in development, utilizes Probody technology to induce tumor cell death and activate anticancer immunity. Early-stage research related to the core technology is currently underway. The refractory disease treatment ISU304 (Dalcinonacog Alfa, a treatment for hemophilia B) is a new drug under development for the prevention of hemophilia B caused by a deficiency of coagulation Factor IX (FIX). After Phase 1 clinical trials, a joint development agreement was signed with U.S.-based Catalyst Biosciences, and safety and efficacy were confirmed through Phase 2 trials. ISU305 (Eculizumab) is a biosimilar of Soliris®, the paroxysmal nocturnal hemoglobinuria treatment developed by Alexion Pharmaceuticals. It demonstrated biological equivalence to Soliris and confirmed safety and tolerability through Phase 1 clinical trials in Australia and New Zealand.

Public

Biotech